TY - JOUR
TI - Avascular necrosis of the femoral head: Evaluation of hyperbaric oxygen therapy and quality of life.
AU - Chandrinou, Angeliki
AU - Korompeli, Anna
AU - Grammatopoulou, Eirini
AU - Gaitanou, Konstantina
AU - Tsoumakas, Konstantinos
AU - Fildissis, George
JO - Undersea & hyperbaric medicine : journal of the Undersea and Hyperbaric Medical Society, Inc
PY - 2020
VL - 47
TODO - 4
SP - 561--569
PB - 
SN - null
TODO - 10.22462/10.12.2020.5
TODO - Humans, Adult, Female, Male, *Quality of Life, Prospective Studies, Analysis of Variance, Time Factors, * bone necrosis, * health status, * health surveys, * orthopedics, * pain, * research, Femur Head Necrosis/*therapy, Hyperbaric Oxygenation/*methods
TODO - INTRODUCTION: The treatment of avascular necrosis of the femoral head (AVNFH) is based on invasive (e.g., core decompression) and non-invasive methods (e.g.,  hyperbaric oxygen therapy - HBO2). The purpose of the present study is to evaluate  the effect of HBO2 on the quality of life (QoL) of patients with AVNFH. METHODS:  This was a prospective observational non-controlled study of patients with AVNFH  treated by HBO2. It was conducted, with the use of Steinberg scale, on 73 patients  with AVNFH Stage I or II who were treated with HBO2. Patients’ QoL was assessed with  EuroQol-5D-5L (EQ), Harris Hip Score (mHHS), MAHORN (MHOT), and VAS, in three  different phases: before HBO2; after the completion of the first phase (20 HBO2  sessions, up to two months); and after the completion of the second phase (20 HBO2  sessions, up to two months after the first phase). A reassessment was made on the  completion of each phase. Ratings were also made after the completion of each phase,  over the first five months of follow-up. RESULTS: All 73 patients (67.1% males,  32.9% females, mean age: 40.34, SD ±± 9.99) participated in the study. Steinberg  scale, mean EQ (F (1, 57) = 25.18, η2 = .306 and F (1, 43) = 43.402, η2 = .502);  mHHS (F (1, 61) = 67.13, η2 = .524) and F (1, 43) = 31.84, η2 = .425); MHOT (F (1,  61) = 11.68, η2 = .161) and F (1, 43) = 98.01, η2 = .695); and VAS (F (1, 53) =  24.11, η2 = .313) and F (1, 39) = 45.61, η2 = .539), improved between the first and  second measurements and between the second and third measurement accordingly (p <  .01). CONCLUSION: HBO2 treatment does not induce alteration of quality of life and  is well tolerated and accepted by patients.
ER -